Skip to content

US · SRTS · MEDICAL - DEVICES

Sensus Healthcare, Inc. (SRTS) intrinsic value and stock valuation

$2.26as of 2026-11-21 · Mkt cap 48.4M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sensus Healthcare, Inc. DCF and intrinsic value

InvestorsCraft values SRTS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SRTS’s statements →

Sensus Healthcare, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Boca Raton, FL 33487 sensushealthcare.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$27.5M+23.5% 5y CAGRd
20132025
Net income
-$-7.72M
20132025
Free cash flow
$330K
20122025
Total equity
$48.1M+17.5% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$27.5M$41.8M$24.4M$44.5M$27M
Operating income-$-10.31M$8.09M-$-380K$14.8M$4.12M
Net income-$-7.72M$6.65M$480K$24.2M$4.12M
EPSd-$-472.75K$406.5K$29.5K$1.46M$249.7K
Operating cash flow$530K-$-830K-$-2.15M-$-1.41M-$-290K
Capital expenditure-$-200K-$-280K-$-230K-$-160K-$-130K
Free cash flow$330K-$-1.11M-$-2.37M-$-1.57M-$-410K
Total assets$53M$62.2M$53.7M$56.7M$32.2M
Total debt$680K$600K$780K$1.02M$230K
Net debt-$-21.4M-$-21.45M-$-22.36M-$-24.5M-$-14.29M
Total equity$48.1M$55.8M$48.8M$48.1M$26M
Cash and short-term investments$22.1M$22.1M$23.2M$25.5M$14.5M
Income statement
20252024202320222021
Revenue$27.5M$41.8M$24.4M$44.5M$27M
Cost of revenue$15.6M$17.4M$10.4M$14.9M$10.1M
Gross profit$11.9M$24.4M$14.1M$29.6M$17M
Research and development expenses$7.78M$4.22M$3.68M$3.46M$3.44M
Selling, general and administrative expenses$14.4M$12.1M$10.8M$11.3M$9.43M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$22.2M$16.3M$14.4M$14.8M$12.9M
Cost and expenses$37.8M$33.7M$24.8M$29.7M$22.9M
Interest income$680K$930K$990K$380K$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$390K$430K$460K$510K$610K
Ebitda-$-9.24M$9.45M$1.11M$28.5M$4.73M
Operating income-$-10.31M$8.09M-$-380K$14.8M$4.12M
Total other income/expenses, net$680K$930K$1.03M$13.2M-$0.00
Income before tax-$-9.62M$9.02M$650K$28M$4.12M
Income tax expense-$-1.91M$2.38M$170K$3.75M$0.00
Net income-$-7.72M$6.65M$480K$24.2M$4.12M
Weighted average shares outstanding$16.3M$16.3M$16.3M$16.5M$16.5M
Weighted average diluted shares outstanding$16.3M$16.4M$16.3M$16.6M$16.5M
Balance sheet
20252024202320222021
Cash and short-term investments$22.1M$22.1M$23.2M$25.5M$14.5M
Net receivables$6.04M$19.7M$10.6M$17.3M$12.1M
Inventory$14.6M$10.1M$11.9M$3.5M$1.76M
Total current assets$45.9M$56.7M$49.5M$53.2M$31.3M
Property, plant and equipment, net$2.43M$2.58M$1.24M$1.24M$770K
Goodwill and intangible assets$0.00$0.00$0.00$50K$150K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$7.15M$5.43M$4.18M$3.49M$990K
Total assets$53M$62.2M$53.7M$56.7M$32.2M
Accounts payable$3.34M$4.81M$2.79M$5.52M$4.06M
Short-term debt$260K$200K$190K$190K$230K
Deferred revenue$840K$540K$660K$690K$1.17M
Total current liabilities$4.72M$5.88M$4.21M$7.7M$5.96M
Long-term debt$420K$400K$600K$830K$0.00
Deferred revenue, non-current$10K$60K$60K$140K$260K
Total non-current liabilities$220K$450K$660K$970K$260K
Capital lease obligations$210K$600K$780K$1.02M$170K
Total liabilities$4.94M$6.34M$4.87M$8.67M$6.22M
Common stock$170K$170K$170K$170K$170K
Retained earnings$5.71M$13.4M$6.79M$6.3M-$-17.94M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$48.1M$55.8M$48.8M$48.1M$26M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$680K$600K$780K$1.02M$230K
Net debt-$-21.4M-$-21.45M-$-22.36M-$-24.5M-$-14.29M
Cash flow statement
20252024202320222021
Net income-$-7.72M$6.65M$480K$24.2M$4.12M
Depreciation and amortization$630K$430K$460K$510K$610K
Stock-based compensation$290K$320K$330K$190K$410K
Change in working capital$8.66M-$-8.55M-$-3.56M-$-12.92M-$-6.14M
Accounts receivable$13.7M-$-9.21M$6.65M-$-5.31M-$-8.43M
Inventory-$-4.63M$270K-$-8.58M-$-3.19M$2.73M
Accounts payable-$-1.47M$2.02M-$-2.73M$800K$960K
Net cash provided by operating activities$530K-$-830K-$-2.15M-$-1.41M-$-290K
Investments in property, plant and equipment-$-200K-$-280K-$-230K-$-160K-$-130K
Acquisitions, net$0.00$0.00$0.00$15M$260K
Net cash used for investing activities-$-200K-$-280K-$-190K$14.8M$130K
Common stock issued$0.00$70K$0.00$0.00$0.00
Common stock repurchased-$-300K$0.00-$-30K-$-3M-$-10K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-300K$10K-$-40K-$-2.43M-$-230K
Net change in cash$30K-$-1.09M-$-2.37M$11M-$-390K
Cash at end of period$22.1M$22.1M$23.2M$25.5M$14.5M
Operating cash flow$530K-$-830K-$-2.15M-$-1.41M-$-290K
Capital expenditure-$-200K-$-280K-$-230K-$-160K-$-130K
Free cash flow$330K-$-1.11M-$-2.37M-$-1.57M-$-410K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sensus Healthcare, Inc.

        Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.

        CEO
        Joseph C. Sardano
        Employees
        60
        Beta
        1.09

        Explore

        Frequently asked questions

        What is the intrinsic value of Sensus Healthcare, Inc. (SRTS)?

        InvestorsCraft does not currently publish an intrinsic value for SRTS. How the IC value is calculated.

        Is SRTS undervalued?

        InvestorsCraft does not publish an undervaluation signal for SRTS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.